Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IASO Signs $162 Million Agreement to Out-License CD19 Binder to Cabaletta For CAR-T

publication date: Oct 11, 2022

Shanghai IASO Biotherapeutics issued an exclusive worldwide license for a fully-human CD19 binder to Philadelphia’s Cabaletta Bio in a deal worth up to $162 million. Cabaletta will use the binder in CABA-201, a CD19-targeting CAR T that aims to be one of the first curative targeted cell therapies for autoimmune diseases. IASO Bio will receive up to $162 million in upfront and milestone payments for two possible candidates, plus royalties. IASO Bio has first negotiation rights to develop and commercialize Cabaletta's products in Greater China.

Stock Symbols: (NSDQ: CABA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital